Guardant Health Inc.
GH evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for GH—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GH
Guardant Health Inc. is a precision oncology company that develops blood-based and tissue-based liquid biopsy tests for cancer detection and monitoring, with a focus on expanding clinical adoption and biopharmaceutical partnerships.
Key risk: Revenue variability and reversal risk
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2026.
Tracking 5 clinical trials for Guardant Health Inc..
Guardant Health Inc. is a precision oncology company that develops blood-based and tissue-based liquid biopsy tests for cancer detection and monitoring, with a focus on expanding clinical adoption and biopharmaceutical partnerships.
- As of June 30, 2026, Guardant Health reported cash, cash equivalents, and restricted cash of $1.2 billion [sec_mda · as of 2026-07-30].
- Total revenue for the six months ended June 30, 2026 was $335.0 million, with a net loss of $120.1 million [latest reported financials].
- The company has an accumulated deficit and negative shareholders' equity of -$305.5 million as of June 30, 2026 [latest reported financials].
- Guardant Health's revenue depends on attracting and maintaining relationships with biopharmaceutical customers for companion diagnostic development and clinical studies [sec_mda · as of 2025-10-29].
- The company expects to continue incurring operating losses as it invests in clinical studies, product development, and sales expansion [sec_mda · as of 2026-02-19].
What works
- Guardant Health holds a substantial cash position of $1.2 billion as of June 30, 2026, providing liquidity for ongoing operations and investments [sec_mda · as of 2026-07-30].
- The company is experiencing growing demand from physicians and biopharmaceutical companies for its tests, which supports revenue growth potential [sec_mda · as of 2026-07-30].
- Guardant Health has established relationships with biopharmaceutical customers for companion diagnostic development and clinical studies, creating recurring revenue opportunities [sec_mda · as of 2025-10-29].
What to weigh
- Guardant Health has a history of net losses and negative shareholders' equity of -$305.5 million as of June 30, 2026, indicating ongoing financial challenges [latest reported financials].
- Revenue is subject to variability and unpredictability due to factors such as coding changes and cash collection adjustments, which could lead to revenue reversals [sec_mda · as of 2025-10-29].
- The company expects operating expenses to increase as it invests in clinical studies, product development, and sales expansion, potentially widening losses [sec_mda · as of 2026-02-19].
- Guardant Health carries significant total debt of $1,502.9 million as of June 30, 2026, which may strain future cash flows [latest reported financials].
From the filings
Quoted directly from source documents.
Guardant Health had $1.2 billion in cash as of June 30, 2026.
“As of June 30, 2026, we had cash, cash equivalents, and restricted cash of $1.2 billion.”
SEC MD&A · July 30, 2026
Revenue depends on biopharmaceutical customer relationships.
“Our revenue also depends on our ability to attract, maintain and expand relationships with biopharmaceutical customers.”
SEC MD&A · October 29, 2025
The company expects to continue incurring operating losses.
“We expect to incur additional operating losses in the near future and our operating expenses will increase as we continue to invest in clinical studies and develop new products, expand our sales organization, and increase our marketing efforts to drive market adoption of our tests.”
SEC MD&A · February 19, 2026
Revenue adjustments are unpredictable and could lead to reversals.
“This variability and unpredictability could increase the risk of future revenue reversal and result in our failing to meet any previously publicly stated guidance we may provide.”
SEC MD&A · October 29, 2025
Risks & what to watch (4)›
Key risks
- Revenue variability and reversal risk — Revenue adjustments from cash collections and coding changes could lead to significant reversals, impacting financial guidance [sec_mda · as of 2025-10-29].
- High debt burden — Total debt of $1,502.9 million as of June 30, 2026 may constrain financial flexibility and increase interest costs [latest reported financials].
- Continued operating losses — The company expects additional losses as it invests in growth, which could further erode equity and cash reserves [sec_mda · as of 2026-02-19].
- Dependence on biopharma partnerships — Revenue relies on maintaining and expanding biopharmaceutical customer relationships, which may be subject to competition and contract terms [sec_mda · as of 2025-10-29].
What to watch
- Revenue growth trends and the impact of biopharmaceutical customer contracts on future revenue [sec_mda · as of 2025-10-29].
- Cash burn rate and the company's ability to achieve profitability given ongoing operating losses [sec_mda · as of 2026-02-19].
- Changes in reimbursement policies or coding that could affect test payment levels [sec_mda · as of 2025-10-29].
- Progress in clinical studies and new product development that may drive future adoption [sec_mda · as of 2026-02-19].
Sources: SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Guardant Health Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Guardant Health Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
63.7 months
OCF -$58M · Net income -$120M
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
1 buy · 76 sells (180d)
Runway
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
484
Total value held
$11.53B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 11,553,759 | $1.07B |
| vanguard capital management llc | 11,248,360 | $1.04B |
| vanguard portfolio management llc | 5,837,992 | $539.3M |
| goldman sachs group inc | 4,435,839 | $409.7M |
| two sigma investments, lp | 4,229,531 | $390.7M |
| fmr llc | 4,116,081 | $380.2M |
| geode capital management, llc | 3,508,883 | $324.2M |
| capital international investors | 3,481,318 | $321.6M |
| franklin resources inc | 3,448,193 | $318.5M |
| deep track capital, lp | 3,338,241 | $308.4M |
Showing top 10 of 484 institutional holders of Guardant Health Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 10.1%
- Days to cover
- 5.7
- Shares short
- 12,806,414
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GH short interestGovernance
Frequently asked questions
What is the AI investment thesis for Guardant Health Inc.?
Guardant Health Inc. is a precision oncology company that develops blood-based and tissue-based liquid biopsy tests for cancer detection and monitoring, with a focus on expanding clinical adoption and biopharmaceutical partnerships.
Who is the CEO of Guardant Health Inc.?
Dr. Helmy Eltoukhy Ph.D. is the chief executive officer of Guardant Health Inc. (GH).
Where is Guardant Health Inc. headquartered?
Guardant Health Inc. (GH) is headquartered in Palo Alto, CA, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.